<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003633</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066717</org_study_id>
    <secondary_id>CPMC-IRB-8040</secondary_id>
    <secondary_id>CPMC-IRB-8040-2/9173</secondary_id>
    <secondary_id>NCI-V98-1487</secondary_id>
    <secondary_id>CPMC-IRB-AAAA5741</secondary_id>
    <nct_id>NCT00003633</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of combination&#xD;
      chemotherapy in treating patients with advanced prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated doses of docetaxel and mitoxantrone in combination with&#xD;
           a fixed dose of estramustine and prednisone, when given to patients with advanced&#xD;
           prostate cancer.&#xD;
&#xD;
        -  Characterize the toxicity of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of mitoxantrone and docetaxel. Patients are&#xD;
      stratified into one of two risk groups (good risk group or poor risk group) based on the&#xD;
      number of prior chemotherapy regimen(s) and the occurrence and sites(s) of prior radiation.&#xD;
&#xD;
      All patients receive oral prednisone twice daily on days 0-3, oral estramustine three times&#xD;
      daily on days 1-5, mitoxantrone IV bolus on day 2, and docetaxel IV over 1 hour on day 2.&#xD;
      Courses repeat every 21 days in the absence of unacceptable toxicity and disease progression.&#xD;
      Patients with stable disease may go off treatment after 6 courses.&#xD;
&#xD;
      Dose escalation proceeds independently for each risk group. Cohorts of 3 patients are entered&#xD;
      into each risk group. If 1 of 3 patients at a dose level experiences dose limiting toxicity&#xD;
      (DLT), then 3 additional patients are accrued into this level. If 2 of 6 patients at a dose&#xD;
      level experience DLT, then dose escalation stops and the maximum tolerated dose (MTD) is&#xD;
      defined at the previous dose level. At least 6 patients must be treated at the MTD.&#xD;
&#xD;
      Patients are followed every 3 months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 12 patients (6 in each risk group) will be accrued into this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 1998</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Failure of complete androgen ablation (orchiectomy or LHRH and antiandrogen therapy)&#xD;
             as manifested by at least 1 of the following criteria:&#xD;
&#xD;
               -  Rise in serum PSA greater than 50% of nadir confirmed on 2 measurements 1 week&#xD;
                  apart&#xD;
&#xD;
               -  Appearance of new lesions on bone scan&#xD;
&#xD;
               -  Appearance of new soft-tissue lesions&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No brain or leptomeningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of coagulopathy&#xD;
&#xD;
          -  No myocardial infarction in the last 6 months&#xD;
&#xD;
          -  No history of cardiovascular accident&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorders including psychotic&#xD;
             disorders, dementia, or seizures&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No history of pulmonary embolus&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Testosterone no greater than 3.5 nmol/L&#xD;
&#xD;
          -  No contraindications to glucocorticoid therapy such as uncontrolled diabetes mellitus&#xD;
             or active peptic ulcer disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No other concurrent or prior malignancy in the past 5 years except previously excised&#xD;
             or curatively irradiated nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy (including nonsteroidal antiandrogens,&#xD;
             but not LHRH agonists)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to greater than 30% of bone marrow&#xD;
&#xD;
          -  At least 6 weeks since isotope therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P. Petrylak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

